{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:35:13Z","timestamp":1790757313822,"version":"4.1.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009362","name":"South London and Maudsley NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012176","name":"Maudsley Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cmi.2026.01.014","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:34:13Z","timestamp":1769531653000},"page":"889-899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Bing-Syuan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiann-Jy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Ming","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mein-Woei","family":"Suen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chieh","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yow-Ling","family":"Shiue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Pin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ta","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Sung","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Te","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Pin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Tao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.01.014_bib1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.4093\/dmj.2019.0071","article-title":"Diabetes and the risk of infection: A National Cohort Study","volume":"43","author":"Kim","year":"2019","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.cmi.2026.01.014_bib2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S2213-8587(22)00247-9","article-title":"Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history","volume":"10","author":"Avogaro","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/jdi.12912","article-title":"Incidence and risk of vaginal candidiasis associated with sodium-glucose cotransporter 2 inhibitors in real-world practice for women with type 2 diabetes","volume":"10","author":"Yokoyama","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.cmi.2026.01.014_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1010693","article-title":"Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary","volume":"9","author":"Mascolo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib5","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s13300-019-00699-8","article-title":"Safety of ipragliflozin in patients with type 2 diabetes mellitus: Pooled analysis of phase II\/III\/IV clinical trials","volume":"10","author":"Kashiwagi","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.cmi.2026.01.014_bib6","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1210\/clinem\/dgac558","article-title":"Sodium-glucose cotransporter 2 inhibitors and the risk of pneumonia and septic shock","volume":"107","author":"Li","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cmi.2026.01.014_bib7","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s13300-020-00803-3","article-title":"Safety of ertugliflozin in patients with type 2 diabetes mellitus: Pooled analysis of seven phase 3 randomized controlled trials","volume":"11","author":"Patel","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.cmi.2026.01.014_bib8","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14740338.2020.1782884","article-title":"Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: A pooled analysis of data from five randomized, controlled clinical trials","volume":"19","author":"Watada","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cmi.2026.01.014_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114228","article-title":"Canagliflozin inhibits inflammasome activation in diabetic endothelial cells - Revealing a novel calcium-dependent anti-inflammatory effect of canagliflozin on human diabetic endothelial cells","volume":"159","author":"Li","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cmi.2026.01.014_bib10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc10-1185","article-title":"Diabetes and sepsis: Preclinical findings and clinical relevance","volume":"34","author":"Schuetz","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib11","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1007\/s00125-024-06102-x","article-title":"Diabetes and infection: Review of the epidemiology, mechanisms and principles of treatment","volume":"67","author":"Holt","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmi.2026.01.014_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjsem-2024-002262","article-title":"How to conduct and report checking transitivity and inconsistency in network-meta-analysis: A narrative review including practical worked examples, code and source data for sports and exercise medicine researchers","volume":"10","author":"Belavy","year":"2024","journal-title":"BMJ Open Sport Exerc Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0140-6736(15)61478-7","article-title":"Network meta-analysis: A norm for comparative effectiveness?","volume":"386","author":"Higgins","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib14","article-title":"The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis","author":"Tseng","year":"2025","journal-title":"J R Soc Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12916-025-04018-w","article-title":"The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: Evidence from a network meta-analysis","volume":"23","author":"Tseng","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/ph18050735","article-title":"Risk of hearing loss in patients treated with exendin-4 derivatives: A network meta-analysis of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors","volume":"18","author":"Chen","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.cmi.2026.01.014_bib17","doi-asserted-by":"crossref","first-page":"8202","DOI":"10.3390\/ijms26178202","article-title":"The preventive effects of GLP-1 receptor agonists and SGLT2 inhibitors on cancer metastasis: A network meta-analysis of 67 randomized controlled trials","volume":"26","author":"Hsu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2026.01.014_bib18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/JS9.0000000000003450","article-title":"The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: A network meta-analysis of 68 randomized controlled trials","volume":"112","author":"Hung","year":"2025","journal-title":"Int J Surg"},{"key":"10.1016\/j.cmi.2026.01.014_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-025-01750-x","article-title":"The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: A network meta-analysis of 91 randomized controlled trials","volume":"18","author":"Tseng","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.cmi.2026.01.014_bib20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/ijms27020608","article-title":"Agent- and dose-specific intestinal obstruction safety of GLP-1 receptor agonists and SGLT2 inhibitors: A network meta-analysis of randomized trials","volume":"27","author":"Chen","year":"2026","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2026.01.014_bib21","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3390\/biom15111622","article-title":"Divergent risks of hematologic malignancies associated with GLP-1 receptor agonists and SGLT2 inhibitors: Preliminary findings from a pilot network meta-analysis","volume":"15","author":"Lin","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.cmi.2026.01.014_bib22","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 19: adverse effects","author":"Peryer","year":"2023"},{"key":"10.1016\/j.cmi.2026.01.014_bib23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40265-022-01730-2","article-title":"From skepticism to hope: The evolving concept of the initiation and use of sodium-glucose cotransporter 2 inhibitors in hospitalized patients","volume":"82","author":"Koufakis","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2026.01.014_bib25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/14779072.2023.2273900","article-title":"Adverse events and drug-drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure","volume":"21","author":"Stollberger","year":"2023","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.cmi.2026.01.014_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.NPR.0000718508.65708.a1","article-title":"Infectious complications of newer agents in the fight against diabetes","volume":"45","author":"Stover","year":"2020","journal-title":"Nurse Pract"},{"key":"10.1016\/j.cmi.2026.01.014_bib27","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2026.01.014_bib28","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1001\/jamapsychiatry.2022.1513","article-title":"Assessment of noninvasive brain stimulation interventions for negative symptoms of schizophrenia: A systematic review and network meta-analysis","volume":"79","author":"Tseng","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.cmi.2026.01.014_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): A 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahren","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib31","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib33","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/dom.15079","article-title":"Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials","volume":"25","author":"Aroda","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cmi.2026.01.014_bib34","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/dom.13251","article-title":"Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study","volume":"20","author":"Aronson","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cmi.2026.01.014_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib38","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib39","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","article-title":"Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): A randomised, open-label, phase 3, non-inferiority study","volume":"385","author":"Blonde","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib40","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: The North American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib41","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib42","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib43","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/dom.15019","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cmi.2026.01.014_bib44","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib46","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib47","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.2337\/dc13-0663","article-title":"Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes","volume":"36","author":"Ferrannini","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib48","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.2337\/dc21-2656","article-title":"Efficacy and safety of once-weekly efpeglenatide monotherapy versus placebo in type 2 diabetes: The AMPLITUDE-M randomized controlled trial","volume":"45","author":"Frias","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib50","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib51","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/dc10-1900","article-title":"Exenatide twice daily versus premixed insulin aspart 70\/30 in metformin-treated patients with type 2 diabetes: A randomized 26-week study on glycemic control and hypoglycemia","volume":"34","author":"Gallwitz","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib52","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","article-title":"Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): An open-label, randomised controlled trial","volume":"379","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib54","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib55","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib57","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib58","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/dc14-1625","article-title":"Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)","volume":"38","author":"Giorgino","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","article-title":"Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: The VERTIS RENAL randomized study","volume":"9","author":"Grunberger","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.cmi.2026.01.014_bib60","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dc16-0522","article-title":"Initial combination of empagliflozin and metformin in patients with type 2 diabetes","volume":"39","author":"Hadjadj","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib61","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib62","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.diabres.2017.06.013","article-title":"Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy","volume":"131","author":"Home","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.cmi.2026.01.014_bib64","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib65","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): A double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib66","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2337\/dc15-2782","article-title":"Glucose Variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib67","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","article-title":"Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes","volume":"70","author":"Januzzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cmi.2026.01.014_bib68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib69","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/dom.15041","article-title":"Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel study","volume":"25","author":"Ji","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cmi.2026.01.014_bib70","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","article-title":"Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): A multicentre, randomised, open-label, parallel-group, phase 3 trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib71","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/dom.13218","article-title":"Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial","volume":"20","author":"Kaku","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cmi.2026.01.014_bib72","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cmi.2026.01.014_bib73","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib74","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.clinthera.2015.05.511","article-title":"Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus","volume":"37","author":"Kovacs","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2026.01.014_bib75","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial","volume":"56","author":"Lavalle-Gonzalez","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmi.2026.01.014_bib76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s13300-023-01515-0","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as metformin add-on in a Korean population with type 2 diabetes","volume":"15","author":"Lee","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.cmi.2026.01.014_bib77","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/dom.12666","article-title":"Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease","volume":"18","author":"Leiter","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cmi.2026.01.014_bib78","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib79","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): A double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib80","series-title":"Bexagliflozin Efficacy and Safety Trial (BEST)","author":"Lock","year":"2021"},{"key":"10.1016\/j.cmi.2026.01.014_bib81","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): A 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib82","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): A randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib83","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib84","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib85","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2337\/dc15-0779","article-title":"Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes","volume":"38","author":"Mathieu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib86","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib87","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): A placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib88","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): A double-blind, multicentre, randomised controlled trial","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib89","first-page":"CD015588","article-title":"Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes","volume":"5","author":"Natale","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2026.01.014_bib90","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib91","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00125-015-3795-1","article-title":"Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"59","author":"Nauck","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmi.2026.01.014_bib92","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib93","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib94","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib95","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib96","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): A multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib98","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00125-014-3196-x","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes","volume":"57","author":"Polidori","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmi.2026.01.014_bib99","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): A randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib101","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstrale","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib102","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 Trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib103","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.01.014_bib104","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/dc14-0001","article-title":"Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: A comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib105","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: The SURPASS-6 randomized clinical trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.01.014_bib106","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2337\/dc12-2709","article-title":"Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib107","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.01.014_bib108","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.01.014_bib109","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib110","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: The CHIEF-HF remote, patient-centered randomized trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib111","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007995.2013.850066","article-title":"Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATA-M study","volume":"30","author":"Stenlof","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cmi.2026.01.014_bib112","series-title":"A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease (SURMOUNT-J)","year":"2024"},{"key":"10.1016\/j.cmi.2026.01.014_bib113","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib114","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: A randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.014_bib115","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cmi.2026.01.014_bib116","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2337\/dc21-2034","article-title":"Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease: Pooled analysis of placebo-controlled clinical trials","volume":"45","author":"Tuttle","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib117","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib118","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib119","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/jdi.13888","article-title":"Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan","volume":"13","author":"Wada","year":"2022","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.cmi.2026.01.014_bib120","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.01.014_bib121","series-title":"Efficacy and safety of sotagliflozin versus placebo in participants with type 2 diabetes mellitus who have inadequate glycemic control while taking insulin alone or with other oral antidiabetic agents (SOTA-INS)","author":"Wason","year":"2021"},{"key":"10.1016\/j.cmi.2026.01.014_bib122","series-title":"Efficacy and Bone safety of sotagliflozin 400 and 200 mg versus placebo in participants with type 2 diabetes mellitus who have inadequate glycemic control (SOTA-BONE)","author":"Wason","year":"2021"},{"key":"10.1016\/j.cmi.2026.01.014_bib123","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/dom.12479","article-title":"Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): A randomized, phase III study","volume":"17","author":"Weinstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cmi.2026.01.014_bib124","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s00125-014-3360-3","article-title":"HARMONY 4: Randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea","volume":"57","author":"Weissman","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmi.2026.01.014_bib125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib126","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib127","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib128","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2026.01.014_bib129","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib130","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","first-page":"7","article-title":"Chapter 11: Undertaking network meta-analyses","author":"Chaimani","year":"2018"},{"key":"10.1016\/j.cmi.2026.01.014_bib131","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.cmi.2026.01.014_bib132","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/jrsm.1373","article-title":"MetaInsight: An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta","volume":"10","author":"Owen","year":"2019","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.cmi.2026.01.014_bib133","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J"},{"key":"10.1016\/j.cmi.2026.01.014_bib134","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010983","article-title":"Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: A simulation study","volume":"6","author":"Cheng","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2026.01.014_bib135","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1002\/sim.6301","article-title":"The Peto odds ratio viewed as a new effect measure","volume":"33","author":"Brockhaus","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib136","series-title":"Converting Among Effect Sizes","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.cmi.2026.01.014_bib137","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2026.01.014_bib138","author":"Phillippo"},{"key":"10.1016\/j.cmi.2026.01.014_bib139","article-title":"GRADE approach to drawing conclusions from a network meta-analysis using a partially contextualised framework","volume":"371","author":"Brignardello-Petersen","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2026.01.014_bib140","first-page":"15","article-title":"Assessing the influence of a single study in meta-analysis","volume":"47","author":"Tobias","year":"1999","journal-title":"Stata Tech Bull"},{"key":"10.1016\/j.cmi.2026.01.014_bib141","series-title":"CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS)","year":"2009"},{"key":"10.1016\/j.cmi.2026.01.014_bib142","series-title":"A study of the effects of canagliflozin (JNJ-28431754) on renal endpoints in adult participants with type 2 diabetes mellitus (CANVAS-R)","year":"2014"},{"key":"10.1016\/j.cmi.2026.01.014_bib143","series-title":"The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)","year":"2010"},{"key":"10.1016\/j.cmi.2026.01.014_bib144","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fcell.2019.00108","article-title":"Sepsis: Inflammation is a necessary evil","volume":"7","author":"Nedeva","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.cmi.2026.01.014_bib145","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmi.2026.01.014_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.820541","article-title":"Canagliflozin ameliorates NLRP3 inflammasome-mediated inflammation through inhibiting NF-kappaB signaling and upregulating Bif-1","volume":"13","author":"Niu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cmi.2026.01.014_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109697","article-title":"The role of NLRP3 inflammasome in sepsis: A potential therapeutic target","volume":"115","author":"He","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.cmi.2026.01.014_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101367","article-title":"Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors","volume":"48","author":"Wu","year":"2022","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.cmi.2026.01.014_bib149","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/geriatrics10040108","article-title":"Effect of anti-diabetic medication use on sepsis risk in type 2 diabetes mellitus: A multivariate analysis","volume":"10","author":"Ulambayar","year":"2025","journal-title":"Geriatrics (Basel)"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26000194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26000194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:48:51Z","timestamp":1778759331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26000194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":149,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1198743X26000194"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.01.014","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}